Redhill Divests Talicia To Apotex For $18 Million Cash Upfront Plus Milestones - RDHL News | RalliesRedhill Divests Talicia To Apotex For $18 Million Cash Upfront Plus Milestones
R
RDHL• Redhill sells Talicia rights to Apotex
- Redhill Biopharma Ltd said it is divesting Talicia® to Apotex for $18 million cash upfront plus milestones to fuel strategic growth opportunities.
- Apotex will receive Redhill's 70% interest in Talicia after its prior acquisition of Cumberland's 30% stake.
- Apotex will pay $18 million upfront plus up to $35 million in worldwide net sales milestones.
•
